当前位置:首页 / 尼妥珠单抗联合吉西他滨治疗局部晚期或转移性胰腺癌的临床疗效及对血清肿瘤标志物、炎性因子和癌组织相关蛋白的影响
| 更新时间:2026-11-20
|
尼妥珠单抗联合吉西他滨治疗局部晚期或转移性胰腺癌的临床疗效及对血清肿瘤标志物、炎性因子和癌组织相关蛋白的影响
Clinical efficacy of nimotuzumab combined with gemcitabine in the treatment of locally advanced or metastatic pancreatic cancer and its effects on serum tumor markers, inflammatory cytokines and cancer tissue-related proteins

内科 页码:519-524

作者机构:河南大学第一附属医院消化病科,河南省开封市 475000

基金信息:河南省科技发展计划(252300420119)

DOI:10.16121/j.cnki.cn45-1347/r.2026.05.02

  • 中文简介
  • 英文简介
  • 参考文献

目的 探讨尼妥珠单抗联合吉西他滨治疗局部晚期或转移性胰腺癌的临床疗效及对血清肿瘤标志物、炎性因子和癌组织相关蛋白表达的影响。方法 选取2022年1月至2025年7月河南大学第一附属医院收治的86例局部晚期或转移性胰腺癌患者,采用随机数字表法将其分为对照组和观察组,每组43例。对照组给予吉西他滨治疗,观察组在对照组基础上加用尼妥珠单抗,两组均持续治疗3个月。比较两组临床疗效、血清肿瘤标志物水平、血清炎性因子水平,癌组织中肿瘤相关蛋白表达水平及Ki-67增殖指数,以及不良反应总发生率。结果 观察组疾病控制率(DCR)高于对照组(93.02%比72.09%,P=0.011),但两组客观缓解率差异无统计学意义(67.44%比51.16%,P=0.124)。治疗前,两组血清肿瘤标志物、血清炎性因子、癌组织中肿瘤相关蛋白表达水平及Ki-67增殖指数差异均无统计学意义(均P>0.05);治疗3个月后,观察组血清糖类抗原(CA)19-9、CA125、癌胚抗原、C反应蛋白、白细胞介素-6、肿瘤坏死因子-α水平,癌组织中表皮生长因子受体、人类表皮生长因子受体2、β-连环蛋白表达水平,以及Ki-67增殖指数均低于对照组,E-钙黏蛋白表达水平高于对照组(均P<0.05)。观察组不良反应总发生率低于对照组(6.98%比25.58%,P=0.019)。结论 尼妥珠单抗联合吉西他滨治疗可提高局部晚期或转移性胰腺癌患者的DCR,下调血清肿瘤标志物及炎性因子水平,调控癌组织增殖、侵袭相关蛋白表达,并减少不良反应。

Objective To investigate the clinical efficacy of nimotuzumab combined with gemcitabine in the treatment of locally advanced or metastatic pancreatic cancer and its effects on serum tumor markers, inflammatory cytokines and the expression of cancer tissue-related proteins. Methods A total of 86 patients with locally advanced or metastatic pancreatic cancer admitted to the First Affiliated Hospital of Henan University from January 2022 to July 2025 were selected, and divided into a control group and an observation group using a random number table method, with 43 cases in each group. The control group received gemcitabine treatment, while the observation group received additional nimotuzumab on the basis of the control group; both groups were treated continuously for 3 months. The clinical efficacy, the serum tumor marker levels, the serum inflammatory cytokine levels, the expression levels of tumor-related proteins in cancer tissue and the Ki-67 proliferation index, and the total incidence of adverse reactions were compared between the two groups. Results The disease control rate (DCR) in the observation group was higher than that in the control group (93.02% vs. 72.09%, P=0.011), but there was no statistically significant difference in the objective response rate between the two groups (67.44% vs. 51.16%, P=0.124). Before treatment, there were no statistically significant differences in the serum tumor markers, serum inflammatory cytokines, the expression levels of tumor-related proteins in cancer tissue, or the Ki-67 proliferation index between the two groups (all P>0.05). After 3 months of treatment, the observation group had lower levels of serum carbohydrate antigen (CA) 19-9, CA125, carcinoembryonic antigen, C-reactive protein, interleukin-6, and tumor necrosis factor-α, lower expression levels of epidermal growth factor receptor, human epidermal growth factor receptor 2, and β-catenin in cancer tissue, and a lower Ki-67 proliferation index than the control group, while the expression level of E-cadherin was higher than that in the control group (all P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (6.98% vs. 25.58%, P=0.019). Conclusion Nimotuzumab combined with gemcitabine can improve the DCR in patients with locally advanced or metastatic pancreatic cancer, downregulate the levels of serum tumor markers and inflammatory cytokines, regulate the expression of proteins related to cancer cell proliferation and invasion in cancer tissue, and reduce adverse reactions.

    无

5

浏览量

0

下载量

0

CSCD

工具集